Serum Exosome With High Osteogenesis and High Angiogenesis for Bone Defect Repair
Summary
USPTO granted Patent US12599630B2 to Peking University School and Hospital of Stomatology for a serum exosome composition with high osteogenesis and high angiogenesis for bone defect repair. The patent covers exosomes derived from serum during fracture recovery period (weeks 2-5 post-fracture) and methods of preparing and using them for bone defect repair. The patent contains 5 claims.
What changed
USPTO granted Patent US12599630B2 covering serum exosomes extracted from fracture recovery period serum (weeks 2-5 post-fracture) with enhanced osteogenic and angiogenic properties for bone defect repair applications. The patent names Hao Liu, Yongsheng Zhou, Wei Li, and Ranli Gu as inventors.
For pharmaceutical and biotechnology companies developing exosome-based bone repair therapies, this patent establishes intellectual property rights held by Peking University in the US market. Parties developing similar serum exosome compositions for bone defects should conduct freedom-to-operate analyses and consider licensing discussions with the assignee.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Serum exosome with high osteogenesis and high angiogenesis, preparation method, and application thereof
Grant US12599630B2 Kind: B2 Apr 14, 2026
Assignee
Peking University School and Hospital of Stomatology
Inventors
Hao Liu, Yongsheng Zhou, Wei Li, Ranli Gu
Abstract
A serum exosome with high osteogenesis and high angiogenesis, a preparation method and an application thereof are provided, which belongs to the field of bone defect repair technologies. The serum exosome is derived from a serum in a fracture recovery period, and the fracture recovery period is in a range of a second week to a fifth week after fracture. It has been found that the exosomes extracted from the serum after fracture have stronger osteogenic and angiogenic properties than exosomes extracted from normal serum, which is helpful to solve problems that large segmental bone defects, extensive traumas and other diseases are difficult to repair, and provide a new therapy for all diseases that need to be repaired and cured through osteogenic and/or angiogenic properties.
CPC Classifications
A61K 35/16 A61K 9/127 A61P 19/08
Filing Date
2022-10-12
Application No.
17964100
Claims
5
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.